AC
VRTX icon

Armistice Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Armistice Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,239
Closed -$15.8M – 492
2025
Q3 		$15.8M Buy
+40,239
New +$16.8M 0.23% 67
2025
Q2 		– Sell
-50,000
Closed -$24.2M – 273
2025
Q1 		$24.2M Sell
50,000
-174,016
-78% -$81.1M 0.36% 57
2024
Q4 		$90.2M Buy
224,016
+177,887
+386% +$82.5M 1.23% 10
2024
Q3 		$21.5M Buy
46,129
+10,070
+28% +$4.84M 0.34% 51
2024
Q2 		$16.9M Sell
36,059
-15,921
-31% -$6.91M 0.21% 74
2024
Q1 		$21.7M Sell
51,980
-46,020
-47% -$19.5M 0.29% 63
2023
Q4 		$39.9M Sell
98,000
-18,117
-16% -$6.69M 0.54% 34
2023
Q3 		$40.4M Sell
116,117
-7,883
-6% -$2.76M 0.62% 32
2023
Q2 		$43.6M Sell
124,000
-96,000
-44% -$32.3M 0.63% 34
2023
Q1 		$69.3M Buy
220,000
+72,000
+49% +$21.6M 1% 24
2022
Q4 		$42.7M Sell
148,000
-2,000
-1% -$610K 0.75% 31
2022
Q3 		$43.4M Sell
150,000
-162,000
-52% -$46.6M 0.75% 34
2022
Q2 		$87.9K Buy
312,000
+76,000
+32% +$20.3M 1.53% 13
2022
Q1 		$61.6M Sell
236,000
-252,000
-52% -$59.8M 1.19% 24
2021
Q4 		$107M Sell
488,000
-148,000
-23% -$28.8M 1.75% 10
2021
Q3 		$115M Buy
636,000
+36,000
+6% +$7.03M 1.95% 6
2021
Q2 		$121M Buy
600,000
+208,000
+53% +$43.5M 2.17% 5
2021
Q1 		$84.2M Buy
+392,000
New +$86.1M 1.93% 7
2020
Q1 		– Sell
-65,000
Closed -$14.2M – 102
2019
Q4 		$14.2M Buy
65,000
+35,000
+117% +$7.08M 0.82% 39
2019
Q3 		$5.08M Buy
+30,000
New +$5.31M 0.34% 53

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Armistice Capital's VRTX Position: Q4 2025 in Review

Armistice Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 40,239 shares — an estimated $15.8M sold.

Armistice Capital first reported a position in VRTX in Q3 2019 and held it in 20 quarters. The position peaked at $121M in Q2 2021. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Armistice Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Armistice Capital sold 40,239 Vertex Pharmaceuticals shares in Q4 2025, an estimated $15.8M.
  • Armistice Capital first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 20 quarters.
  • Armistice Capital's Vertex Pharmaceuticals position peaked at $121M in Q2 2021.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.